Sputum eosinophilia identifies systemic corticosteroid responsiveness in acute exacerbations of COPD Source: Annual Congress 2011 - Mechanism and monitoring of airway diseases Year: 2011
Increased levels of osteopontin in sputum supernatant in patients with COPD Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012
Association of the severe, frequent exacerbation phenotype with exercise capacity, sputum bacteriology and copeptin circulating levels in COPD Source: Annual Congress 2011 - Diagnosis and predictors of COPD exacerbation Year: 2011
Change of induced sputum TNF-a and sTNF-R55,75 levels in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Respiratory pathophysiology Year: 2007
Il-6 levels in sera and induced sputum of COPD patients during exacerbations and stable period Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005
Increased levels of osteopontin in sputum supernatant in smoking asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017
The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005
Sputum eosinophil levels in corticosteroid-treated asthmatic patients Source: Annual Congress 2011 - Mechanism and monitoring of airway diseases Year: 2011
Are blood inflammatory markers useful in characterising children with severe asthma (SA)? Source: Annual Congress 2010 - Fibre-optic bronchoscopy and bronchoalveolar lavage in the treatment of paediatric respiratory diseases Year: 2010
Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017
Decreased levels of myeloperoxidase in induced sputum of COPD patients after oral glucocorticoids treatment Source: Eur Respir J 2002; 20: Suppl. 38, 404s Year: 2002
Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018
Changes of IL-6 level in bronchoalveolar fluid in patients with acute exacerbation of COPD before and after the treatment with tiotropium bromide, and its significance Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
Correlation between ECP in induced sputum and asthma symptoms in children treated with budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 450s Year: 2001
Increased levels of hyaluronan in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 436s Year: 2003
Procalcitonin versus C-reactive protein in the management of severe acute exacerbations of COPD Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010
Serum ECP levels do not correlate with degree of bronchial hyperresponsiveness in patients with cough variant asthma Source: Eur Respir J 2005; 26: Suppl. 49, 584s Year: 2005
Serum levels of IL-8 is related to airflow limitation in mild and severe asthma Source: Eur Respir J 2003; 22: Suppl. 45, 548s Year: 2003
Factors associated with elevated FeNO in infants with recurrent respiratory symptoms Source: Annual Congress 2011 - Early wheezing conditions in childhood Year: 2011